In pilot clinical studies using patient serum samples assayed by surface plasmon resonance (SPR), SubB2M detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers.
“SubB2M is potentially one of the most exciting breakthroughs in cancer diagnostics that I have seen in 40 years of medical research."
Not much $ but the news will put it back on the buy side and watch this space lists.
Ann: BARD1 Awarded BTB Funding to Develop Breast Cancer Test, page-3
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.5¢ |
Change
0.020(4.21%) |
Mkt cap ! $55.20M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 49.5¢ | 47.0¢ | $36.17K | 75.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 8947 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |